167 related articles for article (PubMed ID: 38267108)
1. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic.
Csonka D; Fishman V; Natarajan J; Stieltjes H; Armas D; Dishy V; Perez Ruixo JJ
Pharmacol Res Perspect; 2021 Oct; 9(5):e00846. PubMed ID: 34624174
[TBL] [Abstract][Full Text] [Related]
3. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed-dose combination tablets versus the use of single-component tablets in healthy subjects.
Ford JL; Sabet A; Natarajan J; Stieltjes H; Chao DL; Goyal N; Csonka D
Pharmacol Res Perspect; 2024 Jun; 12(3):e1202. PubMed ID: 38764241
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.
Grill S; Bruderer S; Sidharta PN; Antonova M; Globig S; Carlson J; Schultz A; Csonka D
Br J Clin Pharmacol; 2020 Dec; 86(12):2424-2434. PubMed ID: 32374030
[TBL] [Abstract][Full Text] [Related]
6. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
7. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
9. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
[TBL] [Abstract][Full Text] [Related]
11. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
12. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
13. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
Jansa P; Pulido T
Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
[TBL] [Abstract][Full Text] [Related]
16. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
[TBL] [Abstract][Full Text] [Related]
19. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
20. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2024 Apr; 12(4):e21-e30. PubMed ID: 38548406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
